Children With HIV May Benefit From Alendronate
Alendronate treatment is well-tolerated and improved bone mineral density (BMD) with no safety concerns in children and adolescents with perinatally acquired HIV.
Alendronate treatment is well-tolerated and improved bone mineral density (BMD) with no safety concerns in children and adolescents with perinatally acquired HIV.
Evidence on intervention effectiveness in improving uptake and retention of mothers and infants in the prevention of mother-to-child transmission care in HIV regimens is lacking.
Preterm infants are undervaccinated at 19 and 36 months when compared with infants born at term or postterm.
Elderly patients with HIV who have cancer, and specifically breast and prostate cancer, may have worse outcomes when compared with elderly patients without HIV with cancer.
In women with HIV and diabetes mellitus, CD4+ lymphocytes may contribute to the development of diabetes mellitus.